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OBJECTIVES: Patients with advanced NSCLC have a poor prognosis—with median 
overall survival of less than one year. A randomized clinical trial (RCT) of bevaci-
zumab plus chemotherapy vs. chemotherapy alone demonstrated a signiﬁcant 
(2-month) improvement in median survival. However, a cost-effectiveness analysis of 
this therapy has not been published. Based on the RCT results, we performed a cost-
utility and cost-effectiveness analysis to evaluate the cost-effectiveness of bevacizumab 
added to chemotherapy in patients with advanced NSCLC. METHODS: We devel-
oped a Markov model to project quality-adjusted life years (QALYs) and direct 
medical costs from a US health care payer perspective in patients treated with beva-
cizumab plus chemotherapy vs. chemotherapy alone. Survival and toxicity data for 
the model came from the RCT (ECOG 4599). We obtained utilities from a literature 
search and unit costs from Medicare. We discounted QALYs and costs at 3% per 
year. We addressed uncertainty with one-way and probabilistic sensitivity analyzes. 
RESULTS: Compared to chemotherapy alone, bevacizumab and chemotherapy 
increased mean life expectancy by 0.23 years and mean QALYs by 0.13, at an incre-
mental lifetime cost of US$71,000 per patient. The projected incremental cost-effec-
tiveness ratios (ICERs) were US$309,000/life-year gained and US$557,000/QALY 
gained, respectively. Sensitivity analysis showed that the cost-effectiveness was most 
sensitive to the number of cycles of bevacizumab, its unit cost, and the utility in stable 
disease state during treatment. CONCLUSIONS: Based on commonly cited cost-
effectiveness thresholds, bevacizumab is not projected to be cost-effective for these 
trial patients from a payer perspective (but without accounting for any possible price 
assistance programs). An analysis from the societal perspective could generate different 
results. These ﬁndings might help decision-makers to make informed decisions about 
resource allocation for advanced NSCLC care.
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OBJECTIVES: To examine the cost-utility of two treatment strategies utilizing cetux-
imab plus platinum-doublet chemotherapy as ﬁrst-line treatment in Stage IIIB/IV 
non-small cell lung cancer relative to chemotherapy only from a U.S. societal perspec-
tive. METHODS: A decision analytic model was developed to estimate direct medical 
costs, patient time costs, and quality-adjusted life-years (QALYs) for three treatment 
strategies: 1) chemotherapy+cetuximab for all patients; 2) chemotherapy+cetuximab 
for one month and continued for patients experiencing rash; and 3) chemotherapy 
only. Model parameters were derived from the pivotal trial of cetuximab, published 
literature, and government sources. The model included trial-based adverse events and 
costs related to drug treatment, routine follow-up, AEs, and post-progression care. 
The model results were examined using one-way and probabilistic sensitivity analyses 
(PSA). RESULTS: Total QALYs for the chemotherapy+cetuximab for all, treat-to-
rash, and chemotherapy only strategies were 0.608, 0.610, and 0.574, respectively. 
Total costs were $175,532; $154,174; and $101,164, respectively. Relative to chemo-
therapy only, chemotherapy+cetuximab and treat-to-rash strategies had incremental 
cost-effectiveness ratios of $2,219,000 and $1,470,000 per QALY, respectively. Rela-
tive to chemotherapy+cetuximab for all, the treat-to-rash strategy had a cost-savings 
of $21,358, and a small increase in QALYs. One-way sensitivity analyses found results 
to be sensitive to the cost and required dose of cetuximab, cost of care after progres-
sion, and progression-free and overall survival. In the PSA, chemotherapy only had 
the highest probability of being cost effective until a willingness-to-pay of $1,400,000; 
after which treat-to-rash had the highest probability. CONCLUSIONS: These results 
suggest that the addition of cetuximab to chemotherapy for this patient population is 
not a cost-effective alternative to chemotherapy only by any plausible standard of 
willingness-to-pay. However, if clinicians still wish to treat with cetuximab due to the 
recommendations of oncology practice guidelines, a treat-to-rash strategy may be a 
cost-effective alternative to chemotherapy+cetuximab for all patients with negligible 
impact on QALYs.
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OBJECTIVES: Trastuzumab (Herceptin®) as an adjuvant treatment for patients with 
early stage HER2+ve breast cancer, following surgery, chemotherapy and radiotherapy 
has been shown to reduce disease recurrence by ∼50% and the risk of death at 2 years 
by ∼33% (Piccart-Gebhart 2005). The objective of this analysis was therefore to 
determine the cost effectiveness of 1-year treatment with trastuzumab following stan-
dard chemotherapy vs observation for patients with HER2+ve EBC in the Romanian 
setting from the National Health Insurance House perspective. METHODS: A ﬁve 
health states Markov model was developed, using published results from HERceptin 
Adjuvant trial. Overall survival of patients was simulated over a projected 45 years 
lifetime horizon. Utility values for health states and events were taken from published 
literature. Direct medical costs were included. Resource use was based on expert 
opinion from the two biggest oncology centers in Romania. Unit costs (2009) were 
derived from Romanian retail prices for drugs, diagnostic and monitoring tests and 
procedures, day-hospital and inpatient stays costs. Costs were discounted by 5%. 
Sensitivity analyses were performed. RESULTS: This analysis showed that the incre-
mental cost per patient for adjuvant trastuzumab therapy would be 26,462 EUR on 
average. Beneﬁt to the patient would be 3.11 QALY, on average, in a 45 years time 
horizon. The incremental cost per QALY gained for adjuvant trastuzumab versus 
observation would be 8,498 EUR. Sensitivity analysis for different scenarios (0% costs 
and outcomes, 5% costs and outcomes, 5% costs and 0% outcomes) indicated results 
were sensitive to the discount rate, but the ICER remained below 20,000 EUR/QALY. 
CONCLUSIONS: Trastuzumab for the adjuvant treatment of HER2+ve EBC patients 
shows to be cost-effective from the Romanian National Health Insurance House 
perspective.
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OBJECTIVES: To perform an economic evaluation of Dasatinib for the treatment 
of Chronic Myeologenous Leukaemia (CML) in patients resistant to imatinib in 
Colombia and Venezuela, using the efﬁcacy data found in the study entitled “An 
Economic Evaluation of Dasatinib for the treatment of Chronic Myelogenous Leu-
kaemia in Imatinib—Resistant Patients”, which was carried out by the York con-
sortium, UK. METHODS: On the same initial assumptions of the York work as 
regards to population, age of start, time horizon and discount rate, and adjusting 
the rates of mortality due to other causes, we used a Markov model which would 
enable a prediction of costs and health beneﬁts obtained during the entire lifetime 
for each of the treatment options. RESULTS: In the chronic phase of the disease, 
dasatinib yielded 6.33 and 6.03 QALYs for Colombia and Venezuela respectively, 
in comparison with 6.03 and 5.73 QALYs in the case of nilotinib. In Colombia, 
with an ICER of $54,120,910 per QALY, stated in 2009 Colombian pesos, dasatinib 
showed a better cost-effectiveness ratio than nilotinib, and in Venezuela, dasatinib 
proved to be dominant. In the accelerated phase, dasatinib produced 3.5 times more 
QALYs than those of the imatinib group in both countries. In the blastic phase, 
QALYs were 3,4 times more than those of the imatinib group. CONCLUSIONS: 
Dasatinib at a dose of 140 mg/day showed a better cost-effectiveness ratio than the 
doses of 800 mg of Imatinib and 800 mg of Nilotinib for the treatment of patients 
with CML resistant to usual imatinib doses in the chronic phase, as well as in the 
accelerated and blastic phases.
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OBJECTIVES: Compare Multiple Myeloma (MM) treatment patterns and resource 
consumption in the Nordic countries. METHODS: A modiﬁed Delphi-panel was 
designed, consisting of 14 haematologists at different university hospital clinics in 
Norway, Denmark, Finland, and Sweden. In a 3-round process with structured ques-
tionnaires in February 2007 to January 2008, resources utilisation was surveyed 
including drugs, tests, bone marrow transplantations (BMT), hospital in/outpatient 
stay/visits, radiotherapy, surgical- and diagnostic procedures. RESULTS: Patient char-
acteristics were slightly different with mean age ranging from 67 to 70; age above 65 
years 52%-64%; males 55%-64%; co-morbidities 47%-63%. Differences were found 
in the time spent in 1st line treatment (Norway 18 months; Finland 7 months) and the 
share of patients continuing on to 2nd and 3rd lines (Norway 38% and 22%; Finland 
89% and 72%, respectively). Melphalan and prednisone combination in 1st line was 
used in all countries. Differences in the introduction of thalidomide, bortezomib and 
lenalidomide were seen, with Denmark treating 24% of the patients with bortezomib 
and lenalidomide in 1st line. This could be driven by differences in the number of 
clinical studies (1%–40%). The prescription rate of blood enhancement drugs 
and BMT was highest in Sweden. The number of hospitalisation-days per patient-
month ranged between 0.4 (Denmark) to 1.4 (Finland) in 1st line but increased with 
line of treatment in all countries. Denmark on the other hand had more outpatient 
visits. Radiotherapy was highest in Sweden and Denmark. Small differences were seen 
in other resource categories. CONCLUSIONS: Although Nordic treatment guidelines 
for MM from 2005 are well accepted (excl. Finland) some differences in treatment 
patterns were seen. These could reﬂect differences in patient characteristics, clinical 
trials and a non-synchronised development of new treatment guidelines. Also differ-
ences in political decisions, relative prices and health care organisations may have an 
impact.
